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In April 2012, a cluster of two cases of meningococ-
cal disease caused by rifampicin-resistant C meningo-
cocci was reported in the Champagne-Ardenne region, 
France. The two cases occurred in a student popula-
tion living in the same town but studying at different 
schools. Bacteriological and epidemiological investi-
gations of cases have shown that the isolates of both 
cases were non-differentiable.
Background
Neisseria meningitidis is a strictly human bacterium 
encountered in the pharynx in about 10% of the general 
population (asymptomatic carriage) [1]. This bacterium 
can also cause severe infections (mainly septicemia 
and meningitis) [2].
In France, the annual incidence of invasive meningococ-
cal disease (IMD) varies between 0.9 and 1.5 cases per 
100,000 population. Cases are mainly due to meningo-
cocci of serogroup B and C (65% and 27% respectively 
for the last 10 years) [3]. Chemoprophylactic treatment 
with rifampicin is particularly useful in preventing sec-
ondary cases among close contacts of a patient with 
IMD and in stopping the spread of pathogenic N. men-
ingitidis. Rifampicin is recommended as first-line agent 
for chemoprophylaxis among contacts of patients with 
IMD in several European countries [4]. The efficacy 
of the chemoprophylaxis is usually estimated by the 
reduction of carriage rate of meningococci. This reduc-
tion has been reported to range between 82% and 98% 
at 7–14 days of follow-up [5–7]. Resistant meningococ-
cal isolates may emerge among 10–27% of treated 
carriers [8, 9]. However, several studies have reported 
that rifampicin resistance is rare in invasive meningo-
coccal isolates [10]. According to the annual report of 
the National Reference Center for Meningococci (NRCM) 
in Paris, the incidence of rifampicin-resistant menin-
gococci isolated in France averages one per year with 
no expansion of these isolates and no secondary case 
[11]. We describe here the detection of a cluster of two 
cases of rifampicin-resistant C meningococci that were 
reported in the Champagne-Ardenne region, France in 
2012. 
Case reports
A student in his early twenties (Case one) presenting 
with signs of meningitis was admitted mid-April 2012 
to a hospital, in the Ile-de-France region. The case who 
lived and studied in a town in the Champagne-Ardenne 
region, close to the Ile-de-France region, was immedi-
ately treated with cefotaxime and amoxicillin. Cultures 
of the patient’s cerebrospinal fluid (CSF) and blood 
taken upon admission, yielded serogroup C menin-
gococci. Following the French recommendations [12], 
rifampicin was recommended to the family and other 
close contacts three days hereafter, when the health 
agency in the Champagne-Ardenne region had received 
the notification. In addition to rifampicin, vaccination 
with meningococcal C conjugate vaccine was recom-
mended for household contacts. 
Eleven days after the notification of Case one, the 
health agency in the Champagne-Ardenne region 
received another notification of IMD. A student in 
his late teens (Case two) had been admitted the day 
before with signs of meningitis to a hospital, in the 
Champagne-Ardenne region and was immediately 
treated with cefotaxime and amoxicillin. Case two lived 
and studied in the same city as Case 1 but attended a 
different school, The CSF and blood cultures of Case 
two also yielded serogroup C meningococci. 
Family and close contacts of Case two were given the 
same recommendations as those of Case one. On the 
second day after admission of Case two, antibiotic 
sensitivity testing results showed that the strain was 
rifampicin-resistant. As a result, chemoprophylaxis for 
contacts was recommended to be repeated with cipro-
floxacin or ceftriaxone [12]. 
At the same time, the health agency in the Champagne-
Ardenne region was informed that the strain of Case 
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one was also rifampicin-resistant. However, it was then 
too late (delay >10 days), according to the French rec-
ommendations [12], to repeat chemoprophylaxis with 
ciprofloxacin or ceftriaxone for the contacts of the 
Case one.
Epidemiological investigations found that Case two 
had attended a party organised by the schoolmates of 
Case one two days after admission of the first case. 
Molecular typing
Strains of both cases were sent to the NRCM in Paris 
where phenotyping and genotyping was performed and 
rifampicin resistance confirmed. The characterisation 
by multilocus sequence typing, PorA variable regions, 
penA, FetA showed that the isolates were non-differ-
entiable. The antigenic formula (serogroup: serotype: 
subtype) was C: NT: P1.7, 1. The genetic typing showed 
PorA VR1=7-1, VR2=1, FetA= F3-6 and penA3, and the 
strains were of the sequence type ST-11 (clonal complex 
ST-11). The resistance was due to the same mutation in 
the rpoB (D542V) that was previously reported to con-
fer resitance to rifampicin [9]. A retrospective analysis 
revealed that in March 2012, a strain with identical 
markers had been isolated in a neighbouring region to 
the Champagne-Ardenne region. The patient was also 
a student, but we found no epidemiological link with 
the first and second cases described in this report.  
Discussion and conclusion 
In April 2012, at an approximate interval of 10 days, we 
observed two cases of IMD caused by rifampicin-resist-
ant C meningococcus in students in the Champagne-
Ardenne region. Failure of chemoprophylaxis, due to 
antibiotic resistance, could lead to the occurrence 
of secondary cases [13–15]. Therefore, the use of 
rifampicin in chemoprophylaxis against already resist-
ant bacteria creates a positive selection for resistant 
strains that may then provoke secondary cases. The 
detection of the cluster of two cases with non-differ-
entiable isolates of rifampicin-resistant C meningo-
cocci suggests the possible carriage and circulation 
of the ST-11 strain in the student population of the 
Champagne-Ardenne region.  
We could assume that Case one could have transmitted 
N. meningitidis to one or more of his contacts before 
admission. Contacts of Case one could then have 
transmitted it to Case two during the party organised 
on 18 April. 
Indeed, ST-11 serogroup C isolates (rifampicin sus-
ceptible) have been circulating in the northwestern 
part of France during the last two years in particular 
among student populations (unpublished data). This 
circulation and the repeated use of rifampicin in 
chemoprophylaxis may have accounted for the selec-
tion of rifampicin resistant ST-11 serogroup C isolates. 
Our detection of a case in a neighbouring region to 
the Champagne-Ardenne region in March 2012 (but 
unlinked to the reported cluster) due to rifampicin 
resistant ST-11 serogroup C isolates is in accordance 
with the hypothesis of the selection of rifampicin-
resistant strain [10]. 
It is worth to note here that ST-11 isolates belonged to 
a hyperinvasive genotype that was one of the reasons 
to recommend systemic vaccination in France in 2009 
among 1-24 year-olds, which has now been imple-
mented [16, 17]. Our report underlines the need to mon-
itor antibiotic resistance and both bacteriological and 
epidemiological investigations of cases even without 
obvious historical links in order to adapt chemopro-
phylaxis to the resistance profile of locally circulating 
strains.
To date, no new case of IMD had been notified in the 
local student population. Concerning this population, 
it is recommended to administer ciprofloxacin or cef-
triaxone as chemoprophylaxis as soon as possible to 
protect contacts by reducing carriage of the strain if a 
new case of IMD occurs. This is recommended by the 
French High Council for Public Health on 16 April, 2012 
[18]. The French recommendations insist on the impor-
tance of vaccination against C meningococcus using 
meningococcal C conjugate vaccine in 1-24 year-olds. 
The occurrence of IMD is an opportunity to remind the 
population and physicians  of this recommendation [17, 
19].
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